A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma

Abstract

Background The tumor immunological microenvironment (TIME) has a prominent impact on prognosis and immunotherapy. However, the heterogeneous TIME and the mechanisms by which TIME affects immunotherapy have not been elucidated in hepatocellular carcinoma (HCC). Methods A total of 2195 eligible HCC patients from TCGA and GEO database were collected. We comprehensively explored the different heterogeneous TIME phenotypes and its clinical significance. The potential immune escape mechanisms and what genomic alterations may drive the formation of different phenotypes were further investigated. Results We identified three phenotypes in HCC: TIME-1, the “immune-deficiency” phenotype, with immune cell depletion and proliferation; TIME-2, the “immune-suppressed” phenotype, with enrichment of immunosuppressive cells; TIME-3, the “immune-activated phenotype”, with abundant leukocytes infiltration and immune activation. The prognosis and sensitivity to both sorafenib and immunotherapy differed among the three phenotypes. We also underlined the potential immune escape mechanisms: lack of leukocytes and defective tumor antigen presentation capacity in TIME-1, increased immunosuppressive cells in TIME-2, and rich in immunoinhibitory molecules in TIME-3. The different phenotypes also demonstrated specific genomic events: TIME-1 characterized by TP53, CDKN2A, CTNNB1, AXIN1 and FOXD4 alterations; TIME-2 characterized by significant alteration patterns in the PI3K pathway; TIME-3 characterized by ARID1A mutation. Besides, the TIME index (TI) was proposed to quantify TIME infiltration pattern, and it was a superior prognostic and immunotherapy predictor. A pipeline was developed to classify single patient into one of these three subtypes and calculated the TI. Conclusions We identified three TIME phenotypes with different clinical outcomes, immune escape mechanisms and genomic alterations in HCC, which could present strategies for improving the efficacy of immunotherapy. TI as a novel prognostic and immunotherapeutic signature that could guide personalized immunotherapy and clinical management of HCC.

AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma

“…In addition, Liao et al (38) reported that CXCL8 secreted by HCC cells makes a tumorigenic inflammatory microenvironment to promote epithelialmesenchymal transition and HCC invasion by MAPK pathway. Better understanding the immune subtypes of HCC could guide personalized immunotherapy and clinical management of HCC (39). And a recent study published in the journal of GUT has been identified that administration of p38 MAPK inhibitor could restrain monocytic myeloid-derived suppressor cell to suppress the proliferation of HCC, indicating that MAPK signaling pathway was closely related to immune microenvironment of HCC (40).…”

PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers

“…The classical chemokines and markers of macrophages and EMT signaling pathway were also included (21)(22)(23)(24). Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was applied to get individual immunotherapy response (25,26), and individual chemotherapeutic response was predicted based on Genomics of Drug Sensitivity in Cancer (GDSC) database (27,28). Drug sensitivity prediction was perform using R package 'pRRophetic' (29).…”

Comprehensive Molecular Analyses of a Six-Gene Signature for Predicting Late Recurrence of Hepatocellular Carcinoma

“…HCC is the fifth most common tumor worldwide and the fourth most common cause of cancer-related deaths in China ( 14 ). Although advances in the treatment and management of patients with HCC have improved survival rates to some extent, it still has a high rate of recurrence, limiting long-term survival even after surgical resection.…”